A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2) Meeting Abstract
| Authors: | Shih, J.; Yang, C.; Su, W.; Hsia, T.; Tsai, C.; Chen, Y.; Chang, H.; Terlizzi, E.; Shahidi, M.; Miller, V. A. |
| Abstract Title: | A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2) |
| Meeting Title: | 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 27 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2009 May 29-Jun 2 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2009-05-20 |
| Start Page: | 410s |
| Language: | English |
| ACCESSION: | WOS:000276606605216 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2009.27.15_suppl.8013 |
| Notes: | Meeting Abstract: 8013 -- Source: Wos |
